Sage Therapeutics conference call on FDA meeting

Management discusses the FDA’s joint advisory committees favorable decision in support of the Company’s New Drug Application for ZULPRESSO (Brexanolone) for treatment of Postpartum Depression, as well as 3Q earnings results, on a conference call to be held on November 6 at 8 am.

Webcast: https://edge.media-server.com/m6/p/aovm7p5x
https://thefly.com/landingPageNews.php?id=2816993